This Article Full Text Full Text (PDF) Other Versions of this Article: JCM.01670-06v1 45/4/1126    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Han, X. Y. Search for Related Content PubMed PubMed Citation Articles by Han, X. Y.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, April 2007, p. 1126-1132, Vol. 45, No. 4
0095-1137/07/$08.00+0     doi:10.1128/JCM.01670-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Epidemiologic Analysis of Reactivated Cytomegalovirus Antigenemia in Patients with Cancer

Department of Laboratory Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Received 13 August 2006/ Returned for modification 22 December 2006/ Accepted 26 January 2007

The epidemiologic features of reactivated cytomegalovirus (CMV) antigenemia were studied among 4,382 cancer patients who were cared for and tested at the University of Texas M. D. Anderson Cancer Center from 2001 to 2004. The effects of stem cell transplant (SCT) status, underlying disease, age, sex, ethnicity, and antibody status (prior to CMV exposure) on the incidence of CMV antigenemia were determined; and the CMV burdens were quantified. Antigenemia occurred in 9.3% of patients with non-SCT (n = 2511), 12.0% with autologous SCT (n = 582), and 39.1% with allogeneic SCT (n = 1289). Non-SCT patients with lymphoid tumors had a significantly higher rate of antigenemia than those with myeloid tumors (13.6% versus 3.9%) (P < 0.001); however, after allogeneic SCT, the underlying diseases had little effect, except for multiple myeloma (56.8%) (P = 0.014). Among the allogeneic SCT recipients, higher CMV antigenemia rates were also associated with female sex, older age, and positivity for pre-SCT CMV antibody. Depending on the underlying disease and its associated initial CMV risk, allogeneic SCT increased the risk by 2.6- to 29.6-fold (overall, 4.0-fold). With or without SCT, Asians had the highest CMV antigenemia rates and burdens, followed by blacks, Hispanics, and whites, and these partially correlated with antibody prevalence. Among the 808 patients with antigenemia, the circulating peak CMV burden was significantly higher among non-SCT patients (geometric mean, 18.7 positive cells per 10⁶ leukocytes) than among allogeneic SCT patients (geometric mean, 7.7 positive cells per 10⁶ leukocytes) or autologous SCT patients (geometric mean, 7.0 positive cells per 10⁶ leukocytes) who underwent monitoring for CMV. Together, these results allow stratification of CMV risks and suggest a substantial CMV reactivation among non-SCT cancer patients and, thus, the need for better diagnosis and control.

Published ahead of print on 7 February 2007.